Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: the eagle who wrote (720)	2/20/1998 10:25:00 PM
From: David Cathcart	Read Replies (1) \| Respond to of 1826

Eagle, << what the time frame for getting the drug approved if trials go well [?]>> I'm a little uncertain on this issue but, from what I understand, we would be looking at 2 - 3 more years. Can others help? << anyone have an estimate as to the price tag for europe rights. will these two rights sell be enough to offset the burn rate to get new drug to approval. [?] Blitzer is hesitant to say too much about the price they are expecting for European rights for MGI-114. It is clear that he thinks the drug is extremely valuable. He has said that the possibility exists that revenue from the NCI and the European deal will totally offset the phase II costs for MGI-114. When you think about it, that is all they really need. If MGI-114 flunks phase II, it has costs us nothing if you accept Blitzer's premise. We just move on and appreciate the profits from Salagen. If MGI-114 is successful in phase II, there will likely be no problem finding whatever funds are needed to complete phase III. If the MGI-114 is what RDB thinks it could be, everyone will be trying to get on the bandwagon after phase II. David